Peptide P60
Based on 1 publication(s) in Google Scholar
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4+CD25+Foxp3+ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome.
For research use only. We do not sell to patients.
- Purity : 98.39%
- CAS No.: 1319725-20-6
- Formula: C95H132N24O20S2
- Molecular Weight:1994.34
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Peptide P60
More
Biological Activity
Description
IC50 & Target
[1]|
FOXP3 |
In Vitro
Peptide P60 (5 μM; 60 s association, 30 s dissociation) specifically binds to recombinant human FOXP3 protein in cell-free surface plasmon resonance assays[1].
Peptide P60 (10 μM; 2-18 min) can enter live Jurkat T cells, with its intracellular accumulation detectable within 2 min and reaching a peak at 10 min of incubation[1].
Peptide P60 (100 μM; 24 h) inhibits the nuclear translocation of transiently transfected FOXP3 in human embryonic kidney 293 cells, partially restores the NF-κB transcriptional activity suppressed by FOXP3 overexpression in human embryonic kidney 293 cells, and rescues the NFAT transcriptional activity inhibited by FOXP3 overexpression in Jurkat T cells[1].
Peptide P60 (100 μM; 3 days) inhibits the suppressive function of murine or human CD4+CD25+ regulatory T cells (Tregs), restores the proliferation of CD4+CD25− effector T cells from BALB/c mice stimulated with anti-CD3 antibody, and restores the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated with anti-CD3/CD28 magnetic beads[1].
Peptide P60 (100 μM; 3 days) inhibits the suppressive function of mouse or human CD4+CD25+ Treg cells, restores the proliferation of BALB/c mouse effector T cells in mixed lymphocyte reactions with C57BL/6 dendritic cells, and restores the proliferation of human peripheral blood mononuclear cells (PBMCs) in mixed lymphocyte reactions[1].
Peptide P60 (100 μM; 48 h) modulates gene expression in human CD4+CD25− effector T cells stimulated by anti-CD3, reduces the mRNA levels of Foxp3 and IL-10, and increases the mRNA level of IFN-γ[1].
Peptide P60 (100 μM; 48 h) upregulates IL-2 mRNA expression in human CD4+CD25+ regulatory T cells (Tregs) stimulated with IL-2 + anti-CD3, without altering the mRNA levels of Foxp3 or IFN-γ[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Jurkat T cells
-
Concentration:10 μM
-
Incubation Time:2, 4, 6, 8, 10, 14, 18 min
-
Result:Increased intracellular mean fluorescence intensity significantly over time, reaching a peak at 10 min and remaining elevated through 18 min.
Showed no significant increase in intracellular mean fluorescence intensity with the control peptide.
-
Cell Line:Human embryonic kidney 293 cells (transiently transfected with FOXP3-enhanced GFP fusion protein)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Reduced nuclear localization of FOXP3-EGFP significantly, shifting fluorescence to the cytoplasmic compartment.
Caused no change in nuclear localization with the control peptide, and FOXP3-EGFP expression levels were equivalent across groups.
In Vivo
When administered in combination with the AH1 peptide vaccine, Peptide P60 (50 nM/mouse; i.p.; daily; days 0-9 post immunization) increases the tumor-free survival rate of BALB/c mice challenged with CT26 colorectal cancer cells to 82%[1].
When administered in combination with the RAdNS3 vaccine, Peptide P60 (50 nM/mouse; i.p.; daily; days 0-10 after immunization) provides complete protection against recombinant vaccinia virus HCV challenge in BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (CD1) (newborn, treated from day 1 to 10 after birth)[1]
-
Dosage:25 nM/mouse
-
Administration:i.p.; daily; day 1 to 10 after birth
-
Result:Induced scurfy-like lymphoproliferative autoimmune syndrome with massive inflammatory infiltrates in lungs, liver, and pancreas, plus splenomegaly.
Reduced spleen CD4+CD25+Foxp3+ T cell frequency to 59.3 ± 2.19% of CD4+ T cells.
Caused male mice to develop shoulder ulcers and skin hyperplasia by 3 months post-birth, with ~50% mortality by that time.
-
Animal Model:BALB/c (female, immunized with AH1 peptide, challenged with CT26 tumor cells)[1]
-
Dosage:50 nM/mouse
-
Administration:i.p.; daily; days 0-9 after immunization
-
Result:Increased splenocyte IFN-γ production in response to AH1 peptide stimulation.
Achieved 82% tumor-free survival in AH1-immunized mice challenged with CT26 tumor cells, compared to 0% in control groups.
-
Animal Model:BALB/c (female, immunized with RAdNS3, challenged with recombinant vaccinia virus vHCV1-3011)[1]
-
Dosage:50 nM/mouse
-
Administration:i.p.; daily; days 0-10 after immunization
-
Result:Provided 100% protection against vHCV1-3011 challenge, with significantly reduced ovarian viral loads compared to RAdNS3-only, saline, or control peptide groups.
Chemical Information
-
CAS No. 1319725-20-6
-
Appearance Solid
-
Molecular Weight 1994.34
-
Formula C95H132N24O20S2
-
Color White to off-white
-
Synonyms
FOXP3 inhibitor P60
-
Sequence
Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met-Trp-Pro-Phe-Phe-Ala-Met
-
Sequence Shortening
RDFQSFRKMWPFFAM
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Discov
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. [Abstract]2026 Mar 28. PMID: 41896541
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (25.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Trophoblast Invasion Assay
The trophoblast invasion assay is commonly based on the Matrigel-coated Transwell invasion system, in which invasive cells migrate through a reconstituted basement membrane matrix toward a chemoattractant gradient, thereby modeling extracellular matrix (ECM) penetration and invasive behavior in vitro. The readout is typically the number of cells that traverse the Matrigel barrier and attach to the lower surface of a porous membrane, reflecting invasive capacity through ECM-like substrates and basement membrane components. This system was originally developed to quantify invasive cell behavior using Matrigel as a basement membrane analog in a Boyden chamber format.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.5014 mL | 2.5071 mL | 5.0142 mL | 12.5355 mL |
| 5 mM | 0.1003 mL | 0.5014 mL | 1.0028 mL | 2.5071 mL | |
| 10 mM | 0.0501 mL | 0.2507 mL | 0.5014 mL | 1.2535 mL | |
| 15 mM | 0.0334 mL | 0.1671 mL | 0.3343 mL | 0.8357 mL | |
| 20 mM | 0.0251 mL | 0.1254 mL | 0.2507 mL | 0.6268 mL | |
| 25 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.5014 mL |